1. From individual to herd protection with pneumococcal vaccines: the contribution of the Cuban pneumococcal conjugate vaccine implementation strategy
- Author
-
Dagmar García-Rivera, Nivaldo Linares-Pérez, Vicente Verez-Bencomo, María Eugenia Toledo-Romaní, Darielys Santana-Mederos, Anaí García-Fariñas, and Yury Valdés-Balbín
- Subjects
0301 basic medicine ,Microbiology (medical) ,Immunity, Herd ,medicine.medical_specialty ,Pediatrics ,Cost-Benefit Analysis ,030106 microbiology ,Pneumococcal conjugate vaccine ,Pneumococcal Infections ,Scientific evidence ,Herd immunity ,lcsh:Infectious and parasitic diseases ,Pneumococcal Vaccines ,03 medical and health sciences ,0302 clinical medicine ,Nasopharynx ,medicine ,Humans ,lcsh:RC109-216 ,030212 general & internal medicine ,Intensive care medicine ,Vaccines, Conjugate ,Cost–benefit analysis ,business.industry ,Vaccination ,Cuba ,Infant ,General Medicine ,medicine.disease ,Clinical trial ,Pneumococcal infections ,Infectious Diseases ,Streptococcus pneumoniae ,Paradigm shift ,Child, Preschool ,business ,medicine.drug - Abstract
A new pneumococcal conjugate vaccine is currently undergoing advanced clinical evaluation prior to its planned introduction in Cuba. The implementation of the pneumococcal vaccination strategy has been designed with consideration of the need to maximize both its direct and indirect effects. A novel approach is suggested, which addresses preschool children as the first-line target group to generate herd immunity in infants and to have an impact on transmission at the community level. The clinical evaluation pipeline is described herein, including evaluations of effectiveness, cost-effectiveness, and impact. The scientific contribution of the Cuban strategy could support a paradigm shift from individual protection to a population effect based on a rigorous body of scientific evidence.
- Published
- 2017